New Strategies for the Use of Antioxidants in Neuroprotection and Neurorecovery

A special issue of Antioxidants (ISSN 2076-3921).

Deadline for manuscript submissions: 30 April 2024 | Viewed by 1682

Special Issue Editors


E-Mail Website
Guest Editor
Department of Biochemistry, University of Medicine and Pharmacy from Craiova, 200349 Craiova, Romania
Interests: neuroinflammation; oxidative stress; ageing; neurodegenerative disorders; autoimmune disorders; neurodevelopmental disorders; nanotechnology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The ageing process is associated with a loss of neuronal function that leads to neurodegeneration. The main cellular alteration is linked with a decline in mitochondrial function and increased oxidative stress. Normal and pathological ageing depend on the response of the repair mechanisms of the cells at the multisystemic level. These mechanisms aim to refresh the cells in order to maintain normal function. Activation of opposing cellular pathways such as autophagy or neurogenesis can prolong healthy ageing and the lifespan. For this Special Issue, we want researchers to submit original research articles and review articles about the role of neuronal function in age-related physiological states and diseases, as well as about recent findings on the neuroprotective mechanisms that stop neuronal loss and control neurorecovery in the elderly. To help bridge the current knowledge gap, this Special Issue includes, but is not limited to, age-related diseases of the central and peripheral nervous system, chronic inflammatory diseases such as multiple sclerosis, ankylosing spondylitis, amyotrophic lateral sclerosis, rheumatoid arthritis, or frailty, as well as healthy ageing. Submissions may address a broad range of topics, including but not limited to the therapeutic potential of bioactive compounds, physical exercise, nutrition, nutriomics, metabolomics, epigenetics, personalized nutrition, oxidative stress, antioxidants, autophagy, nanotechnology, neurodegeneration, and neuroregeneration. We are also interested in research that examines the effects of nutraceuticals or pharmaceuticals related to pharmacokinetics, pharmacodynamics, bioavailability, and efficacy. These may be in vitro or in vivo studies, studies on humans or clinical trials, and dietary intervention studies evaluating impacts on health and diseases or required intake and usage dosage.

We look forward to your submissions.

Dr. Ana-Maria Buga
Dr. Carmen Nicoleta Oancea
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ageing
  • nutrition
  • physical exercise
  • oxidative stress
  • antioxidants
  • autophagy
  • fragility
  • neurodegeneration
  • inflammation
  • nutrigenomics
  • nanotechnology

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

22 pages, 3012 KiB  
Article
A Fisetin Delivery System for Neuroprotection: A Co-Amorphous Dispersion Prepared in Supercritical Carbon Dioxide
by Szymon Sip, Natalia Rosiak, Anna Sip, Marcin Żarowski, Katarzyna Hojan and Judyta Cielecka-Piontek
Antioxidants 2024, 13(1), 24; https://doi.org/10.3390/antiox13010024 - 21 Dec 2023
Cited by 3 | Viewed by 1028
Abstract
Fisetin (FIS), a senolytic flavonoid, mitigates age-related neuroprotective changes. An amorphous FIS dispersion with a co-carrier was prepared using supercritical fluid extraction with carbon dioxide (scCO2). Characterisation, including powder X-ray diffraction and Fourier-transform infrared spectroscopy, confirmed amorphization and assessed intermolecular interactions. [...] Read more.
Fisetin (FIS), a senolytic flavonoid, mitigates age-related neuroprotective changes. An amorphous FIS dispersion with a co-carrier was prepared using supercritical fluid extraction with carbon dioxide (scCO2). Characterisation, including powder X-ray diffraction and Fourier-transform infrared spectroscopy, confirmed amorphization and assessed intermolecular interactions. The amorphous FIS dispersion exhibited enhanced solubility, dissolution profiles, and bioavailability compared to the crystalline form. In vitro, the amorphous FIS dispersion demonstrated antioxidant activity (the ABTS, CUPRAC, DDPH, FRAP assays) and neuroprotective effects by inhibiting acetylcholinesterase and butyrylcholinesterase. FIS modulated gut microbiota, reducing potentially pathogenic gram-negative bacteria without affecting probiotic microflora. These improvements in solubility, antioxidant and neuroprotective activities, and gut microbiome modulation suggest the potential for optimising FIS delivery systems to leverage its health-promoting properties while addressing oral functionality limitations. Full article
Show Figures

Figure 1

Review

Jump to: Research

30 pages, 10080 KiB  
Review
α-Phenyl-N-tert-Butylnitrone and Analogous α-Aryl-N-alkylnitrones as Neuroprotective Antioxidant Agents for Stroke
by José Marco-Contelles
Antioxidants 2024, 13(4), 440; https://doi.org/10.3390/antiox13040440 - 07 Apr 2024
Viewed by 428
Abstract
The recent advances in research on the use of the antioxidant and neuroprotective agent α-phenyl-N-tert-butylnitrone (PBN) for the therapy of stroke have been reviewed. The protective effect of PBN in the transient occlusion of the middle cerebral artery (MCAO) has been [...] Read more.
The recent advances in research on the use of the antioxidant and neuroprotective agent α-phenyl-N-tert-butylnitrone (PBN) for the therapy of stroke have been reviewed. The protective effect of PBN in the transient occlusion of the middle cerebral artery (MCAO) has been demonstrated, although there have been significant differences in the neuronal salvaging effect between PBN-treated and untreated animals, each set of data having quite large inter-experimental variation. In the transient forebrain ischemia model of gerbil, PBN reduces the mortality after ischemia and the neuronal damage in the hippocampal cornu ammonis 1 (CA1) area of the hippocumpus caused by ischemia. However, PBN fails to prevent postischemic CA1 damage in the rat. As for focal cerebral ischemia, PBN significantly reduces cerebral infarction and decreases neurological deficit after ischemia using a rat model of persistent MCAO in rats. Similarly, the antioxidant and neuroprotective capacity of a number of PBN-derived nitrones prepared in the author’s laboratory have also been summarized here, showing their high potential therapeutic power to treat stroke. Full article
Show Figures

Figure 1

Back to TopTop